Michael Keating

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Gunn Shelly R; Bolla Aswani R; Barron Lynn L; Gorre Mercedes E; Mohammed Mansoor S; Bahler David W; Mellink Clemens H M; van Oers Marinus H J; Keating Michael J; Ferrajoli Alessandra; Coombes Kevin R; Abruzzo Lynne V; Robetorye Ryan S
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene.
Quiroga Maite P; Balakrishnan Kumudha; Kurtova Antonina V; Sivina Mariela; Keating Michael J; Wierda William G; Gandhi Varsha; Burger Jan A
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Tam Constantine S; Shanafelt Tait D; Wierda William G; Abruzzo Lynne V; Van Dyke Daniel L; O'Brien Susan; Ferrajoli Alessandra; Lerner Susan A; Lynn Alice; Kay Neil E; Keating Michael J
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Michael Keating (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Gunn Shelly R; Bolla Aswani R; Barron Lynn L; Gorre Mercedes E; Mohammed Mansoor S; Bahler David W; Mellink Clemens H M; van Oers Marinus H J; Keating Michael J; Ferrajoli Alessandra; Coombes Kevin R; Abruzzo Lynne V; Robetorye Ryan S
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene.
Leukemia research 2009;33(9):1276-81.
2009: Quiroga Maite P; Balakrishnan Kumudha; Kurtova Antonina V; Sivina Mariela; Keating Michael J; Wierda William G; Gandhi Varsha; Burger Jan A
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Blood 2009;114(5):1029-37.
2009: Tam Constantine S; Shanafelt Tait D; Wierda William G; Abruzzo Lynne V; Van Dyke Daniel L; O'Brien Susan; Ferrajoli Alessandra; Lerner Susan A; Lynn Alice; Kay Neil E; Keating Michael J
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
Blood 2009;114(5):957-64.
2009: Tsimberidou Apostolia-Maria; Keating Michael J
Treatment of fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2009;115(13):2824-36.
2009: Yin C Cameron; Lin Katherine I-Chun; Ketterling Rhett P; Knudson Ryan A; Medeiros L Jeffrey; Barron Lynn L; Huh Yang O; Luthra Rajyalakshmi; Keating Michael J; Abruzzo Lynne V
Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes.
American journal of clinical pathology 2009;131(5):663-70.
2009: Chen Rong; Wierda William G; Chubb Sherri; Hawtin Rachael E; Fox Judith A; Keating Michael J; Gandhi Varsha; Plunkett William
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Blood 2009;113(19):4637-45.
2009: Tam Constantine S; Abruzzo Lynne V; Lin Katherine I; Cortes Jorge; Lynn Alice; Keating Michael J; Thomas Deborah A; Pierce Sherry; Kantarjian Hagop; Verstovsek Srdan
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
Blood 2009;113(18):4171-8.
2009: Sampath Deepa; Calin George A; Puduvalli Vinay K; Gopisetty Gopal; Taccioli Cristian; Liu Chang-Gong; Ewald Brett; Liu Chaomei; Keating Michael J; Plunkett William
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.
Blood 2009;113(16):3744-53.
2009: Lin Katherine I; Tam Constantine S; Keating Michael J; Wierda William G; O'Brien Susan; Lerner Susan; Coombes Kevin R; Schlette Ellen; Ferrajoli Alessandra; Barron Lynn L; Kipps Thomas J; Rassenti Laura; Faderl Stefan; Kantarjian Hagop; Abruzzo Lynne V
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
Blood 2009;113(14):3168-71.
2009: Burger Jan A; Quiroga Maite P; Hartmann Elena; Bürkle Andrea; Wierda William G; Keating Michael J; Rosenwald Andreas
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.
Blood 2009;113(13):3050-8.
2009: Tsimberidou Apostolia-Maria; Wen Sijin; McLaughlin Peter; O'Brien Susan; Wierda William G; Lerner Susan; Strom Sara; Freireich Emil J; Medeiros L Jeffrey; Kantarjian Hagop M; Keating Michael J
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(6):904-10.
2009: Tsimberidou Apostolia-Maria; Tam Constantine; Abruzzo Lynne V; O'Brien Susan; Wierda William G; Lerner Susan; Kantarjian Hagop M; Keating Michael J
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.
Cancer 2009;115(2):373-80.
2009: Sargent Rachel; Jones Dan; Abruzzo Lynne V; Yao Hui; Bonderover Jaime; Cisneros Marissa; Wierda William G; Keating Michael J; Luthra Rajyalakshmi
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.
The Journal of molecular diagnostics : JMD 2009;11(1):25-34.
2008: Caraway Nancy P; Thomas Elizabeth; Khanna Abha; Payne Linda; Zhang Hua-Zhong; Lin E; Keating Michael J; Katz Ruth L
Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival.
Cancer 2008;114(5):315-22.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; Keating Michael J; O'Brien Susan; Brandt Mark; Pierce Sherry; Freireich Emil J; Medeiros L Jeffrey; Estey Elihu
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.
Cancer 2008;113(6):1370-8.
2008: Trachootham Dunyaporn; Zhang Hui; Zhang Wan; Feng Li; Du Min; Zhou Yan; Chen Zhao; Pelicano Helene; Plunkett William; Wierda William G; Keating Michael J; Huang Peng
Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.
Blood 2008;112(5):1912-22.
2008: Balakrishnan Kumudha; Wierda William G; Keating Michael J; Gandhi Varsha
Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells.
Blood 2008;112(5):1971-80.
2008: Tam Constantine S; O'Brien Susan; Wierda William; Kantarjian Hagop; Wen Sijin; Do Kim-Anh; Thomas Deborah A; Cortes Jorge; Lerner Susan; Keating Michael J
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Blood 2008;112(4):975-80.
2008: Huh Yang O; Lin Katherine I-Chun; Vega Francisco; Schlette Ellen; Yin C Cameron; Keating Michael J; Luthra R; Medeiros L Jeffrey; Abruzzo Lynne V
MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis.
British journal of haematology 2008;142(1):36-44.
2008: Safdar Amar; Rodriguez Gilhen H; Rueda Adriana M; Wierda William G; Ferrajoli Alessandra; Musher Daniel M; O'Brien Susan; Koller Charles A; Bodey Gerald P; Keating Michael J
Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity.
Cancer 2008;113(2):383-7.
2008: Zhang H; Trachootham D; Lu W; Carew J; Giles F J; Keating M J; Arlinghaus R B; Huang P
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(6):1191-9.
2008: Ferrajoli Alessandra; Lee Bang-Ning; Schlette Ellen J; O'Brien Susan M; Gao Hui; Wen Sijin; Wierda William G; Estrov Zeev; Faderl Stefan; Cohen Evan N; Li Changping; Reuben James M; Keating Michael J
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
Blood 2008;111(11):5291-7.
2008: Awais Ahmed; Tam Constantine S; Kontoyiannis Dimitrios; Ferrajoli Alessandra; Duvic Madeleine; Cortes Jorge; Keating Michael J
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(7):e69-71.
2008: Yu Zhifeng; Sun Baohua; Kantarjian Hagop M; Keating Michael J; Amin Hesham M; Sun Xiaoping
Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators.
Leukemia & lymphoma 2008;49(4):751-6.
2008: Tam Constantine S; Otero-Palacios Joselle; Abruzzo Lynne V; Jorgensen Jeffrey L; Ferrajoli Alessandra; Wierda William G; Lerner Susan; O'Brien Susan; Keating Michael J
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
British journal of haematology 2008;141(1):36-40.
2008: Ferrajoli Alessandra; Wierda William G; LaPushin Ruth; O'Brien Susan M; Faderl Stefan; Browning Mary L; Keating Michael J
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
European journal of haematology 2008;80(4):296-8.
2008: Gandhi Varsha; Tam Constantine; O'Brien Susan; Jewell Roxanne C; Rodriguez Carlos O; Lerner Susan; Plunkett William; Keating Michael J
Phase I trial of nelarabine in indolent leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1098-105.
2008: Tsimberidou Apostolia-Maria; Kantarjian Hagop M; Wen Sijin; O'Brien Susan; Cortes Jorge; Wierda William G; Koller Charles; Pierce Sherry; Brandt Mark; Freireich Emil J; Keating Michael J; Estey Elihu H
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):721-30.
2008: Tsimberidou Apostolia M; Wierda William G; Plunkett William; Kurzrock Razelle; O'Brien Susan; Wen Sijin; Ferrajoli Alessandra; Ravandi-Kashani Farhad; Garcia-Manero Guillermo; Estrov Zeev; Kipps Thomas J; Brown Jennifer R; Fiorentino Albert; Lerner Susan; Kantarjian Hagop M; Keating Michael J
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):196-203.
2007: Ault Patricia; Lynn Alice; Tam Constantine S; Medeiros L Jeffrey; Keating Michael J
Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosis.
Leukemia research 2007;31(12):1755-8.
2007: Tsimberidou Apostolia M; Wen Sijin; O'Brien Susan; McLaughlin Peter; Wierda William G; Ferrajoli Alessandra; Faderl Stefan; Manning John; Lerner Susan; Mai Chinh V; Rodriguez Alma M; Hess Mark; Do Kim-Anh; Freireich Emil J; Kantarjian Hagop M; Medeiros L Jeffrey; Keating Michael J
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4648-56.
2007: Catrina Reading F; Schlette Ellen J; Stewart John M; Keating Michael J; Katz Ruth L; Caraway Nancy P
Fine-needle aspiration biopsy findings in patients with small lymphocytic lymphoma transformed to hodgkin lymphoma.
American journal of clinical pathology 2007;128(4):571-8.
2007: Abruzzo Lynne V; Barron Lynn L; Anderson Keith; Newman Rachel J; Wierda William G; O'brien Susan; Ferrajoli Alessandra; Luthra Madan; Talwalkar Sameer; Luthra Rajyalakshmi; Jones Dan; Keating Michael J; Coombes Kevin R
Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.
The Journal of molecular diagnostics : JMD 2007;9(4):546-55.
2007: Khouri Issa F; Saliba Rima M; Admirand Joan; O'Brien Susan; Lee Ming-S; Korbling Martin; Samuels Barry I; Giralt Sergio; Lima de Marcos; Keating Michael J; Champlin Richard E; Bueso-Ramos Carlos
Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.
British journal of haematology 2007;137(4):355-63.
2007: Borthakur Gautam; O'Brien Susan; Wierda William G; Thomas Deborah A; Cortes Jorge E; Giles Francis J; Kantarjian Hagop M; Lerner Susan; Keating Michael J
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2007: Nimmanapalli Ramadevi; Lyu Mi-Ae; Du Min; Keating Michael J; Rosenblum Michael G; Gandhi Varsha
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.
Blood 2007;109(6):2557-64.
2007: Safdar A; Rodriguez G; Rolston K V I; O'Brien S; Khouri I F; Shpall E J; Keating M J; Kantarjian H M; Champlin R E; Raad I I; Kontoyiannis D P
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation.
Bone marrow transplantation 2007;39(3):157-64.
2007: Huh Yang O; Abruzzo Lynne V; Rassidakis George Z; Parry-Jones Nilima; Schlette Ellen; Brito-Bapabulle Vasantha; Matutes Estella; Wotherspoon Andrew; Keating Michael J; Medeiros L Jeffrey; Catovsky Daniel
The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases.
British journal of haematology 2007;136(2):220-8.
2006: Ahmed Bilal; Estey Elihu; Manning John; David Cynthia; Keating Michael J; Kantarjian Hagop; Tsimberidou Apostolia-Maria
Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature.
Haematologica 2006;91(12 Suppl):ECR55.
2006: Pelicano Hélène; Xu Rui-Hua; Du Min; Feng Li; Sasaki Ryohei; Carew Jennifer S; Hu Yumin; Ramdas Latha; Hu Limei; Keating Michael J; Zhang Wei; Plunkett William; Huang Peng
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism.
The Journal of cell biology 2006;175(6):913-23.
2006: Tsimberidou Apostolia-Maria; Kantarjian Hagop; Keating Michael J; Estey Elihu
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Leukemia & lymphoma 2006;47(11):2282-8.
2006: Balakrishnan Kumudha; Nimmanapalli Ramadevi; Ravandi Farhad; Keating Michael J; Gandhi Varsha
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Blood 2006;108(7):2392-8.
2006: O'Brien Susan M; Keating Michael J; Mocarski Edward S
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
Clinical lymphoma & myeloma 2006;7(2):125-30.
2006: Ferrajoli Alessandra; Faderl Stefan; Keating Michael J
Monoclonal antibodies in chronic lymphocytic leukemia.
Expert review of anticancer therapy 2006;6(9):1231-8.
2006: Chemaly Roy F; Ghosh Shubhra; Bodey Gerald P; Rohatgi Nidhi; Safdar Amar; Keating Michael J; Champlin Richard E; Aguilera Elizabeth A; Tarrand Jeffrey J; Raad Issam I
Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center.
Medicine 2006;85(5):278-87.
2006: Tsimberidou Apostolia-Maria; O'Brien Susan; Kantarjian Hagop M; Koller Charles; Hagemeister Fredrick B; Fayad Luis; Lerner Susan; Bueso-Ramos Carlos E; Keating Michael J
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
Cancer 2006;107(6):1294-302.
2006: Faderl Stefan; Rai Kanti; Gribben John; Byrd John C; Flinn Ian W; O'Brien Susan; Sheng Shihong; Esseltine Dixie-Lee; Keating Michael J
Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Cancer 2006;107(5):916-24.
2006: Bruzzi John F; Macapinlac Homer; Tsimberidou Apostolia M; Truong Mylene T; Keating Michael J; Marom Edith M; Munden Reginald F
Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(8):1267-73.
2006: Gandhi Varsha; Plunkett William; Bonate Peter L; Du Min; Nowak Billie; Lerner Susan; Keating Michael J
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):4011-7.
2006: Tsimberidou Apostolia M; Catovsky Daniel; Schlette Ellen; O'Brien Susan; Wierda William G; Kantarjian Hagop; Garcia-Manero Guillermo; Wen Sijin; Do Kim-Anh; Lerner Susan; Keating Michael J
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
Cancer 2006;107(1):125-35.
2006: Tibes Raoul; Keating Michael J; Ferrajoli Alessandra; Wierda William; Ravandi Farhad; Garcia-Manero Guillermo; O'Brien Susan; Cortes Jorge; Verstovsek Srdan; Browning Mary L; Faderl Stefan
Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Cancer 2006;106(12):2645-51.
2006: Ravandi Farhad; Jorgensen Jeffrey L; O'Brien Susan M; Verstovsek Srdan; Koller Charles A; Faderl Stefan; Giles Francis J; Ferrajoli Alessandra; Wierda William G; Odinga Shirley; Huang Xuelin; Thomas Deborah A; Freireich Emil J; Jones Dan; Keating Michael J; Kantarjian Hagop M
Eradication of minimal residual disease in hairy cell leukemia.
Blood 2006;107(12):4658-62.
2006: Tsimberidou Apostolia-Maria; O'Brien Susan; Khouri Issa; Giles Francis J; Kantarjian Hagop M; Champlin Richard; Wen Sijin; Do Kim-Anh; Smith Susan C; Lerner Susan; Freireich Emil J; Keating Michael J
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2343-51.
2006: Thomas Deborah A; Giles Francis J; Albitar Maher; Cortes Jorge E; Verstovsek Srdan; Faderl Stefan; O'Brien Susan M; Garcia-Manero Guillermo; Keating Michael J; Pierce Sherry; Zeldis Jerome; Kantarjian Hagop M
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer 2006;106(9):1974-84.
2006: Tsimberidou Apostolia-Maria; Keating Michael J
Richter's transformation in chronic lymphocytic leukemia.
Seminars in oncology 2006;33(2):250-6.
2006: Thomas Deborah A; Faderl Stefan; O'Brien Susan; Bueso-Ramos Carlos; Cortes Jorge; Garcia-Manero Guillermo; Giles Francis J; Verstovsek Srdan; Wierda William G; Pierce Sherry A; Shan Jianqin; Brandt Mark; Hagemeister Fredrick B; Keating Michael J; Cabanillas Fernando; Kantarjian Hagop
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Pelicano H; Carew J S; McQueen T J; Andreeff M; Plunkett W; Keating M J; Huang P
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(4):610-9.
2006: Tsimberidou Apostolia-Maria; Giles Francis J; Estey Elihu; O'Brien Susan; Keating Michael J; Kantarjian Hagop M
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
British journal of haematology 2006;132(4):398-409.
2006: Oki Yasuhiro; Kantarjian Hagop M; Zhou Xian; Cortes Jorge; Faderl Stefan; Verstovsek Srdan; O'Brien Susan; Koller Charles; Beran Miloslav; Bekele B Nebiyou; Pierce Sherry; Thomas Deborah; Ravandi Farhad; Wierda William G; Giles Francis; Ferrajoli Alessandra; Jabbour Elias; Keating Michael J; Bueso-Ramos Carlos E; Estey Elihu; Garcia-Manero Guillermo
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2006: Carew Jennifer S; Nawrocki Steffan T; Krupnik Yelena V; Dunner Kenneth; McConkey David J; Keating Michael J; Huang Peng
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.
Blood 2006;107(1):222-31.
2006: Faderl Stefan; O'Brien Susan; Keating Michael J
Monoclonal antibody combinations in CLL: evolving strategies.
Best practice & research. Clinical haematology 2006;19(4):781-93.
2005: Zhou Yan; Garcia-Prieto Celia; Carney Dennis A; Xu Rui-hua; Pelicano Helene; Kang Ying; Yu Wensheng; Lou Changgang; Kondo Seiji; Liu Jinsong; Harris David M; Estrov Zeev; Keating Michael J; Jin Zhendong; Huang Peng
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action.
Journal of the National Cancer Institute 2005;97(23):1781-5.
2005: Xu R-H; Pelicano H; Zhang H; Giles F J; Keating M J; Huang P
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(12):2153-8.
2005: Achanta Geetha; Sasaki Ryohei; Feng Li; Carew Jennifer S; Lu Weiqin; Pelicano Helene; Keating Michael J; Huang Peng
Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma.
The EMBO journal 2005;24(19):3482-92.
2005: Chen Rong; Keating Michael J; Gandhi Varsha; Plunkett William
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Blood 2005;106(7):2513-9.
2005: Balakrishnan Kumudha; Wierda William G; Keating Michael J; Gandhi Varsha
Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6745-52.
2005: Wierda William G; Kipps Thomas J; Keating Michael J
Novel immune-based treatment strategies for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6325-32.
2005: Keating Michael J; Rai Kanti R; Wierda William G
Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies.
Clinical advances in hematology & oncology : H&O 2005;3(8):1-10; quiz 11-2.
2005: Abruzzo Lynne V; Wang Jing; Kapoor Mini; Medeiros L Jeffrey; Keating Michael J; Edward Highsmith W; Barron Lynn L; Cromwell Candy C; Coombes Kevin R
Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays.
The Journal of molecular diagnostics : JMD 2005;7(3):337-45.
2005: Keating Michael J; O'Brien Susan; Albitar Maher; Lerner Susan; Plunkett William; Giles Francis; Andreeff Michael; Cortes Jorge; Faderl Stefan; Thomas Deborah; Koller Charles; Wierda William; Detry Michelle A; Lynn Alice; Kantarjian Hagop
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: Balakrishnan Kumudha; Stellrecht Christine M; Genini Davide; Ayres Mary; Wierda William G; Keating Michael J; Leoni Lorenzo M; Gandhi Varsha
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.
Blood 2005;105(11):4455-62.
2005: Kurtzberg J; Ernst T J; Keating M J; Gandhi V; Hodge J P; Kisor D F; Lager J J; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell B S
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3396-403.
2005: Faderl Stefan; Gandhi Varsha; Keating Michael J; Jeha Sima; Plunkett William; Kantarjian Hagop M
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Cancer 2005;103(10):1985-95.
2005: Yin C Cameron; Lin Pei; Carney Dennis A; Handy Beverly C; Rassidakis George Z; Admirand Joan H; Keating Michael J; Medeiros L Jeffrey
Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein.
American journal of clinical pathology 2005;123(4):594-602.
2005: Xu Rui-Hua; Pelicano Helene; Zhou Yan; Carew Jennifer S; Feng Li; Bhalla Kapil N; Keating Michael J; Huang Peng
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.
Cancer research 2005;65(2):613-21.
2005: Faderl Stefan J; Keating Michael J
Treatment of chronic lymphocytic leukemia.
Current hematology reports 2005;4(1):31-8.
2005: Tsimberidou Apostolia-Maria; Keating Michael J
Richter syndrome: biology, incidence, and therapeutic strategies.
Cancer 2005;103(2):216-28.
2005: Tsimberidou Apostolia-Maria; Keating Michael J
Hyperuricemic syndromes in cancer patients.
Contributions to nephrology 2005;147():47-60.
2004: Carew J S; Nawrocki S T; Xu R H; Dunner K; McConkey D J; Wierda W G; Keating M J; Huang P
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(12):1934-40.
2004: Wang J; Coombes K R; Highsmith W E; Keating M J; Abruzzo L V
Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies.
Bioinformatics (Oxford, England) 2004;20(17):3166-78.
2004: Thomas Deborah A; O'Brien Susan; Cortes Jorge; Giles Francis J; Faderl Stefan; Verstovsek Srdan; Ferrajoli Alessandra; Koller Charles; Beran Miloslav; Pierce Sherry; Ha Chul S; Cabanillas Fernando; Keating Michael J; Kantarjian Hagop
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Blood 2004;104(6):1624-30.
2004: Bueso-Ramos Carlos E; Ferrajoli Alessandra; Medeiros L Jeffrey; Keating Michael J; Estrov Zeev
Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells.
Hematology (Amsterdam, Netherlands) 2004;9(4):279-86.
2004: Ferrajoli Alessandra; Keating Michael J
Current guidelines in defining therapeutic strategies.
Hematology/oncology clinics of North America 2004;18(4):881-93, ix.
2004: Jabbour E; Keating M J; Champlin R E; Khouri I F
Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?
Bone marrow transplantation 2004;34(4):289-97.
2004: Lenihan Daniel J; Alencar Alvaro J; Yang Deborah; Kurzrock Razelle; Keating Michael J; Duvic Madeleine
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
Blood 2004;104(3):655-8.
2004: Verstovsek Srdan; Giles Francis J; O'Brien Susan; Faderl Stefan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.
Leukemia research 2004;28(7):707-11.
2004: Tsimberidou Apostolia M; Keating Michael J; Giles Francis J; Wierda William G; Ferrajoli Alessandra; Lerner Susan; Beran Miloslav; Andreeff Michael; Kantarjian Hagop M; O'Brien Susan
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Cancer 2004;100(12):2583-91.
2004: Thomas Deborah A; Faderl Stefan; Cortes Jorge; O'Brien Susan; Giles Francis J; Kornblau Steven M; Garcia-Manero Guillermo; Keating Michael J; Andreeff Michael; Jeha Sima; Beran Miloslav; Verstovsek Srdan; Pierce Sherry; Letvak Laurie; Salvado August; Champlin Richard; Talpaz Moshe; Kantarjian Hagop
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Tsimberidou Apostolia-Maria; Murray James L; O'Brien Susan; Wierda William G; Keating Michael J
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
Cancer 2004;100(10):2195-200.
2004: Ma Yupo; Mansour Adnan; Bekele B Nebiyou; Zhou Xian; Keating Michael J; O'Brien Susan; Giles Francis J; Albitar Maher
The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia.
Cancer 2004;100(10):2167-75.
2004: Khouri I F; Albitar M; Saliba R M; Ippoliti C; Ma Y C; Keating M J; Champlin R E
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
Bone marrow transplantation 2004;33(8):833-7.
2004: Hileman Elizabeth Oldham; Liu Jinsong; Albitar Maher; Keating Michael J; Huang Peng
Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity.
Cancer chemotherapy and pharmacology 2004;53(3):209-19.
2004: Khouri Issa F; Lee Ming-Sheng; Saliba Rima M; Andersson Borje; Anderlini Paolo; Couriel Daniel; Hosing Chitra; Giralt Sergio; Korbling Martin; McMannis John; Keating Michael J; Champlin Richard E
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.
Experimental hematology 2004;32(1):28-35.
2003: Gandhi Varsha; Kantarjian Hagop; Faderl Stefan; Bonate Peter; Du Min; Ayres Mary; Rios Mary Beth; Keating Michael J; Plunkett William
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(17):6335-42.
2003: O'Brien Susan M; Kantarjian Hagop M; Thomas Deborah A; Cortes Jorge; Giles Francis J; Wierda William G; Koller Charles A; Ferrajoli Alessandra; Browning Mary; Lerner Susan; Albitar Maher; Keating Michael J
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
Cancer 2003;98(12):2657-63.
2003: Giles Francis J; Vose Julie M; Do Kim-Anh; Johnson Marcella M; Manshouri Taghi; Bociek Gregory; Bierman Philip J; O'Brien Susan M; Keating Michael J; Kantarjian Hagop M; Armitage James O; Albitar Maher
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
British journal of haematology 2003;123(5):850-7.
2003: Tsimberidou Apostolia M; Estey Elihu; Cortes Jorge E; Garcia-Manero Guillermo; Faderl Stefan; Verstovsek Srdan; Thomas Deborah A; Ferrajoli Alessandra; Keating Michael J; O'Brien Susan; Kantarjian Hagop M; Giles Francis J
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Thomas Deborah A; O'Brien Susan; Bueso-Ramos Carlos; Faderl Stefan; Keating Michael J; Giles Francis J; Cortes Jorge; Kantarjian Hagop M
Rituximab in relapsed or refractory hairy cell leukemia.
Blood 2003;102(12):3906-11.
2003: Lee Jeong N; Giles Fancis; Huh Yang O; Manshouri Taghi; O'Brien Susan; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Molecular differences between small and large cells in patients with chronic lymphocytic leukemia.
European journal of haematology 2003;71(4):235-42.
2003: Pelicano Hélène; Feng Li; Zhou Yan; Carew Jennifer S; Hileman Elizabeth O; Plunkett William; Keating Michael J; Huang Peng
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.
The Journal of biological chemistry 2003;278(39):37832-9.
2003: Giles Francis J; Shi Gary Guangping; Cortes Jorge E; Thomas Deborah; Keating Anna R; Kantarjian Hagop M; Keating Michael J; O'Brien Susan M
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Cancer chemotherapy and pharmacology 2003;52(3):223-8.
2003: Amin Hesham M; Jilani Iman; Estey Elihu H; Keating Michael J; Dey Amanda L; Manshouri Taghi; Kantarjian Hagop M; Estrov Zeev; Cortes Jorge E; Thomas Deborah A; Giles Francis J; Albitar Maher
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Blood 2003;102(5):1866-8.
2003: Gatto Simona; Scappini Barbara; Pham Lan; Onida Francesco; Milella Michele; Ball Greg; Ricci Clara; Divoky Vladimir; Verstovsek Srdan; Kantarjian Hagop M; Keating Michael J; Cortes-Franco Jorge E; Beran Miloslav
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Haematologica 2003;88(8):853-63.
2003: Ferrajoli Alessandra; O'Brien Susan M; Cortes Jorge E; Giles Francis J; Thomas Deborah A; Faderl Stefan; Kurzrock Razelle; Lerner Susan; Kontoyiannis Dimitrios P; Keating Michael J
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Cancer 2003;98(4):773-8.
2003: Tsimberidou A-M; Kantarjian H M; Estey E; Cortes J E; Verstovsek S; Faderl S; Thomas D A; Garcia-Manero G; Ferrajoli A; Manning J T; Keating M J; Albitar M; O'Brien S; Giles F J
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(6):1100-3.
2003: McCarthy Helen; Wierda William G; Barron Lynn L; Cromwell Candy C; Wang Jing; Coombes Kevin R; Rangel Roberto; Elenitoba-Johnson Kojo S J; Keating Michael J; Abruzzo Lynne V
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia.
Blood 2003;101(12):4903-8.
2003: Giles Francis J; Bekele B Nebiyou; O'Brien Susan; Cortes Jorge E; Verstovsek Srdan; Balerdi Maria; Yared Marwan; Zhou Xian; Kantarjian Hagop M; Keating Michael J; Thall Peter; Albitar Maher
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
British journal of haematology 2003;121(4):578-85.
2003: Zhou Yan; Hileman Elizabeth O; Plunkett William; Keating Michael J; Huang Peng
Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents.
Blood 2003;101(10):4098-104.
2003: Faderl Stefan; Thomas Deborah A; O'Brien Susan; Garcia-Manero Guillermo; Kantarjian Hagop M; Giles Francis J; Koller Charles; Ferrajoli Alessandra; Verstovsek Srdan; Pro Barbara; Andreeff Michael; Beran Miloslav; Cortes Jorge; Wierda William; Tran Ngoc; Keating Michael J
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Amin Hesham M; McDonnell Timothy J; Medeiros L Jeffrey; Rassidakis Georgios Z; Leventaki Vasiliki; O'Connor Sean L; Keating Michael J; Lai Raymond
Characterization of 4 mantle cell lymphoma cell lines.
Archives of pathology & laboratory medicine 2003;127(4):424-31.
2003: Tsimberidou Apostolia M; Kantarjian Hagop M; Cortes Jorge; Thomas Deborah A; Faderl Stefan; Garcia-Manero Guillermo; Verstovsek Srdan; Ferrajoli Alessandra; Wierda William; Alvarado Yesid; O'Brien Susan M; Albitar Maher; Keating Michael J; Giles Francis J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2003;97(7):1711-20.
2003: Manshouri Taghi; Do Kim-anh; Wang Xuemei; Giles Francis J; O'Brien Susan M; Saffer Helen; Thomas Deborah; Jilani Iman; Kantarjian Hagop M; Keating Michael J; Albitar Maher
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.
Blood 2003;101(7):2507-13.
2003: Kantarjian Hagop M; O'Brien Susan; Cortes Jorge E; Shan Jianqin; Giles Francis J; Rios Mary Beth; Faderl Stefan H; Wierda William G; Ferrajoli Alessandra; Verstovsek Srdan; Keating Michael J; Freireich Emil J; Talpaz Moshe
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Lu Di; Nounou Randa; Beran Miloslav; Estey Elihu; Manshouri Taghi; Kantarjian Hagop; Keating Michael J; Albitar Maher
The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer 2003;97(2):441-9.
2003: Keating Michael J; Chiorazzi Nicholas; Messmer Bradley; Damle Rajendra N; Allen Steven L; Rai Kanti R; Ferrarini Manlio; Kipps Thomas J
Biology and treatment of chronic lymphocytic leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2003;():153-75.
2002: Keating Michael J
Management of chronic lymphocytic leukemia: a changing field.
Reviews in clinical and experimental hematology 2002;6(4):350-65; discussion 449-50.
2002: Aguayo Alvaro; Kantarjian Hagop M; Estey Elihu H; Giles Francis J; Verstovsek Srdan; Manshouri Taghi; Gidel Christy; O'Brien Susan; Keating Michael J; Albitar Maher
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Onida Francesco; Ball Greg; Kantarjian Hagop M; Smith Terry L; Glassman Armand; Albitar Maher; Scappini Barbara; Rios Mary Beth; Keating Michael J; Beran Miloslav
Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
Cancer 2002;95(8):1673-84.
2002: Giles Francis J; Kantarjian Hagop M; Bekele B Nebiyou; Cortes Jorge E; Faderl Stephan; Thomas Deborah A; Manshouri Taghi; Rogers Anna; Keating Michael J; Talpaz Moshe; O'Brien Susan; Albitar Maher
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Keating M J; O'Brien S; Kontoyiannis D; Plunkett W; Koller C; Beran M; Lerner S; Kantarjian H
Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.
Leukemia & lymphoma 2002;43(9):1755-62.
2002: Ferrajoli Alessandra; Keating Michael J; Manshouri Taghi; Giles Francis J; Dey Amanda; Estrov Zeev; Koller Charles A; Kurzrock Razelle; Thomas Deborah A; Faderl Stefan; Lerner Susan; O'Brien Susan; Albitar Maher
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
Blood 2002;100(4):1215-9.
2002: Faderl S; Keating M J; Do K-A; Liang S-Y; Kantarjian H M; O'Brien S; Garcia-Manero G; Manshouri T; Albitar M
Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(6):1045-52.
2002: Scappini Barbara; Onida Francesco; Kantarjian Hagop M; Dong Li; Verstovsek Srdan; Keating Michael J; Beran Miloslav
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Cancer 2002;94(10):2653-62.
2002: Keating Michael J; Flinn Ian; Jain Vinay; Binet Jacques-Louis; Hillmen Peter; Byrd John; Albitar Maher; Brettman Lee; Santabarbara Pedro; Wacker Bret; Rai Kanti R
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Blood 2002;99(10):3554-61.
2002: Abruzzo Lynne V; Rosales Cecilia M; Medeiros L Jeffrey; Vega Francisco; Luthra Rajyalakshmi; Manning John T; Keating Michael J; Jones Dan
Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.
The American journal of surgical pathology 2002;26(5):630-6.
2002: Tsimberidou Apostolia M; O'Brien Susan M; Cortes Jorge E; Faderl Stefan; Andreeff Michael; Kantarjian Hagop M; Keating Michael J; Giles Francis J
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Leukemia & lymphoma 2002;43(4):767-72.
2002: Oudat R; Keating M J; Lerner S; O'Brien S; Albitar M
Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(4):632-5.
2002: Yamauchi Takahiro; Keating Michael J; Plunkett William
UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes.
Molecular cancer therapeutics 2002;1(4):287-94.
2002: Keating Michael J; O'Brien Susan; Albitar Maher
Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Seminars in oncology 2002;29(1 Suppl 2):70-4.
2002: Onida Francesco; Kantarjian Hagop M; Smith Terry L; Ball Greg; Keating Michael J; Estey Elihu H; Glassman Armand B; Albitar Maher; Kwari Monica I; Beran Miloslav
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Blood 2002;99(3):840-9.
2002: Keating M J; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):205-13.
2002: Coombes Kevin R; Zhang Lin; Bueso-Ramos Carlos; Brisbay Shawn; Logothetis Christopher; Roth Jack; Keating Michael J; McDonnell Timothy J
TAD: a web interface and database for tissue microarrays.
Applied bioinformatics 2002;1(3):155-8.
2002: Khouri I F; Keating M J; Saliba R M; Champlin R E
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation.
Cytotherapy 2002;4(3):217-21.
2001: Scappini B; Onida F; Kantarjian H M; Dong L; Verstovsek S; Keating M J; Beran M
Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3884-93.
2001: Keating M J
Progress in CLL, chemotherapy, antibodies and transplantation.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2001;55(9-10):524-8.
2001: Ferrajoli A; O'Brien S; Keating M J
Alemtuzumab: a novel monoclonal antibody.
Expert opinion on biological therapy 2001;1(6):1059-65.
2001: Yamauchi T; Nowak B J; Keating M J; Plunkett W
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3580-9.
2001: Aboul-Nasr R; O'Brien S; Freireich E J; Ginsberg C F; Kantarjian H M; Koller C A; Keating M J; Albitar M
"T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow.
Leukemia & lymphoma 2001;42(5):1023-31.
2001: Huh Y O; Keating M J; Saffer H L; Jilani I; Lerner S; Albitar M
Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
American journal of clinical pathology 2001;116(3):437-43.
2001: Dabaja B S; O'Brien S M; Kantarjian H M; Cortes J E; Thomas D A; Albitar M; Schlette E S; Faderl S; Sarris A; Keating M J; Giles F J
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
Leukemia & lymphoma 2001;42(3):329-37.
2001: Giles F J; Shen Y; Kantarjian H M; Korbling M J; O'Brien S; Anderlini P; Donato M; Pierce S; Keating M J; Freireich E J; Estey E
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.
Leukemia & lymphoma 2001;42(1-2):67-73.
2001: Ferrajoli A; Manshouri T; Estrov Z; Keating M J; O'Brien S; Lerner S; Beran M; Kantarjian H M; Freireich E J; Albitar M
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):795-9.
2001: O'Brien S M; Kantarjian H; Thomas D A; Giles F J; Freireich E J; Cortes J; Lerner S; Keating M J
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2165-70.
2001: Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez C O; Ramakrishna P; Rosner G L; Hodge J P; O'Brien S; Keating M J
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2142-52.
2001: Fayad L; Keating M J; Reuben J M; O'Brien S; Lee B N; Lerner S; Kurzrock R
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.
Blood 2001;97(1):256-63.
2000: Faderl S; Kantarjian H M; Estey E; Manshouri T; Chan C Y; Rahman Elsaied A; Kornblau S M; Cortes J; Thomas D A; Pierce S; Keating M J; Estrov Z; Albitar M
The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.
Cancer 2000;89(9):1976-82.
2000: Rodriguez J; Keating M J; O'Brien S; Champlin R E; Khouri I F
Allogeneic haematopoietic transplantation for Richter's syndrome.
British journal of haematology 2000;110(4):897-9.
2000: Huang P; Feng L; Oldham E A; Keating M J; Plunkett W
Superoxide dismutase as a target for the selective killing of cancer cells.
Nature 2000;407(6802):390-5.
2000: Rodriguez C O; Plunkett W; Paff M T; Du M; Nowak B; Ramakrishna P; Keating M J; Gandhi V
High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):421-30.
2000: Huang P; Sandoval A; Van Den Neste E; Keating M J; Plunkett W
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2000;14(8):1405-13.
2000: Keating M J
Chronic lymphocytic leukemia . Clinical oral poster session.
Hematology and cell therapy 2000;42(1):35-9.
2000: Giles F J; Wong G C; Clark S J; Pierce S; Kantarjian H M; Keating M J
Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):87-95.
2000: Keating M J; Smith T L; Lerner S; O'Brien S; Robertson L E; Kantarjian H; Freireich E J
Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):71-85.
2000: Estey E H; Pierce S; Keating M J
Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities.
Haematologica 2000;85(3):246-9.
2000: Kisor D F; Plunkett W; Kurtzberg J; Mitchell B; Hodge J P; Ernst T; Keating M J; Gandhi V
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):995-1003.
2000: Haidar M A; Manshouri T; Keating M J; Kantarjian H M; Freireich E J; Mehta K; Albitar M
Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice.
International journal of oncology 2000;16(3):561-5.
2000: Kantarjian H M; O'Brien S; Smith T L; Cortes J; Giles F J; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha C S; Keating M J; Murphy S; Freireich E J
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):547-61.
1999: Partyka S; O'Brien S; Podoloff D; Kantarjian H; Keating M J
The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter's transformation.
Leukemia & lymphoma 1999;36(1-2):151-5.
1999: Giles F J; O'Brien S M; Santini V; Gandhi V; Plunkett W; Seymour J F; Robertson L E; Kantarjian H M; Keating M J
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Leukemia & lymphoma 1999;36(1-2):57-65.
1999: Sacchi S; Kantarjian H M; O'Brien S; Cortes J; Rios M B; Giles F J; Beran M; Koller C A; Keating M J; Talpaz M
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Cancer 1999;86(12):2632-41.
1999: Keating M J
Chronic lymphocytic leukemia.
Seminars in oncology 1999;26(5 Suppl 14):107-14.
1999: Thomas D A; Kantarjian H; Smith T L; Koller C; Cortes J; O'Brien S; Giles F J; Gajewski J; Pierce S; Keating M J
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
Cancer 1999;86(7):1216-30.
1999: Thomas D A; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister F B; Cabanillas F F; Murphy S; Keating M J; Kantarjian H
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2461-70.
1999: Kornblau S M; Thall P F; Estrov Z; Walterscheid M; Patel S; Theriault A; Keating M J; Kantarjian H; Estey E; Andreeff M
The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(7):1758-66.
1999: Estey E H; Thall P F; Pierce S; Cortes J; Beran M; Kantarjian H; Keating M J; Andreeff M; Freireich E
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Blood 1999;93(8):2478-84.
1999: Cortes J E; Kantarjian H M; O'Brien S; Giles F; Keating M J; Freireich E J; Estey E H
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Kantarjian H M; O'Brien S; Smith T L; Rios M B; Cortes J; Beran M; Koller C; Giles F J; Andreeff M; Kornblau S; Giralt S; Keating M J; Talpaz M
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):284-92.
1999: Aguayo A; Cortes J E; Kantarjian H M; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating M J
Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
Cancer 1999;85(1):58-64.
1998: Gandhi V; Plunkett W; Rodriguez C O; Nowak B J; Du M; Ayres M; Kisor D F; Mitchell B S; Kurtzberg J; Keating M J
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3607-15.
1998: Khouri I F; Keating M J; Champlin R
Hematopoietic stem cell transplantation for chronic lymphocytic leukemia.
Current opinion in hematology 1998;5(6):454-9.
1998: Anaissie E J; Kontoyiannis D P; O'Brien S; Kantarjian H; Robertson L; Lerner S; Keating M J
Infections in patients with chronic lymphocytic leukemia treated with fludarabine.
Annals of internal medicine 1998;129(7):559-66.
1998: Keating M J; O'Brien S; Lerner S; Koller C; Beran M; Robertson L E; Freireich E J; Estey E; Kantarjian H
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Blood 1998;92(4):1165-71.
1998: Keating M J
Chronic lymphocytic leukemia in the next decade: where do we go from here?
Seminars in hematology 1998;35(3 Suppl 3):27-33.
1998: Sacchi S; Kantarjian H M; Smith T L; O'Brien S; Pierce S; Kornblau S; Beran M; Keating M J; Talpaz M
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):882-9.
1998: Giles F J; O'Brien S M; Keating M J
Chronic lymphocytic leukemia in (Richter's) transformation.
Seminars in oncology 1998;25(1):117-25.
1998: de Lima M; O'Brien S; Lerner S; Keating M J
Chronic lymphocytic leukemia in the young patient.
Seminars in oncology 1998;25(1):107-16.
1997: Kantarjian H M; Talpaz M; O'Brien S; Kurzrock R; Gutterman J; Keating M J; McCredie K B; Freireich E J
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2723-33.
1997: Keating M J
Leukemia: A model for drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 2):2598-604.
1997: Keating M J; McLaughlin P; Cabanillas F
Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND).
European journal of cancer care 1997;6(4 Suppl):21-6.
1997: Freireich E J; Keating M J
Conclusions regarding leukemia long-term survival.
Cancer 1997;80(11 Suppl):2215-7.
1997: Estey E; deLima M; Strom S; Pierce S; Freireich E J; Keating M J
Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center.
Cancer 1997;80(11 Suppl):2176-80.
1997: Rodriguez C O; Legha J K; Estey E; Keating M J; Gandhi V
Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2107-13.
1997: Li L; Keating M J; Plunkett W; Yang L Y
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Molecular pharmacology 1997;52(5):798-806.
1997: O'Brien S; Kantarjian H; Beran M; Koller C; Talpaz M; Lerner S; Keating M J
Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1631-5.
1997: Sacchi S; Kantarjian H M; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating M J; Talpaz M
Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1997;11(10):1610-6.
1997: Gandhi V; Estey E; Du M; Keating M J; Plunkett W
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1539-45.
1997: Cusack J C; Seymour J F; Lerner S; Keating M J; Pollock R E
Role of splenectomy in chronic lymphocytic leukemia.
Journal of the American College of Surgeons 1997;185(3):237-43.
1997: Iwasaki H; Huang P; Keating M J; Plunkett W
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Blood 1997;90(1):270-8.
1997: Kurzrock R; Strom S S; Estey E; O'Brien S; Keating M J; Jiang H; Adams T; Talpaz M
Second cancer risk in hairy cell leukemia: analysis of 350 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1803-10.
1997: Khouri I F; Przepiorka D; van Besien K; O'Brien S; Palmer J L; Lerner S; Mehra R C; Vriesendorp H M; Andersson B S; Giralt S; Körbling M; Keating M J; Champlin R E
Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.
British journal of haematology 1997;97(2):466-73.
1997: Manshouri T; Yang Y; Lin H; Stass S A; Glassman A B; Keating M J; Albitar M
Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RAR beta and RAR gamma and development of lymphoma.
Blood 1997;89(7):2507-15.
1997: Li L; Liu X; Glassman A B; Keating M J; Stros M; Plunkett W; Yang L Y
Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro.
Cancer research 1997;57(8):1487-94.
1997: Haidar M A; El-Hajj H; Bueso-Ramos C E; Manshouri T; Glassman A; Keating M J; Maher A
Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance.
American journal of hematology 1997;54(3):189-95.
1996: Keating M J; O'Brien S; McLaughlin P; Dimopoulos M; Gandhi V; Plunkett W; Lerner S; Kantarjian H; Estey E
Clinical experience with fludarabine in hemato-oncology.
Hematology and cell therapy 1996;38 Suppl 2():S83-91.
1996: Fayad L; Robertson L E; O'Brien S; Manning J T; Wright S; Hagemeister F; Cabanillas F; Keating M J
Hodgkin's disease variant of Richter's syndrome: experience at a single institution.
Leukemia & lymphoma 1996;23(3-4):333-7.
1996: Haidar M A; Loya F; Yang Y; Lin H; Glassman A; Keating M J; Goldwasser E; Albitar M
Differential expression of lacZ in the liver and kidney of transgenic mice carrying chimeric lacZ-erythropoietin gene constructs with or without its 1.2 kb 3'-flanking sequence.
Nucleic acids research 1996;24(18):3621-8.
1996: Ghaddar H M; Pierce S; Kantarjian H M; Freireich E J; Keating M J; Estey E H
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Leukemia & lymphoma 1996;22(1-2):71-6.
1996: Anderlini P; Ghaddar H M; Smith T L; Pierce S; Kantarjian H M; O'Brien S; Keating M J; Freireich E J; Estey E H
Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(6):964-9.
1996: Gandhi V; Estey E H; Keating M J; Plunkett W
Intracellular pharmacodynamics in leukemia therapy.
[Rinsho ketsueki] The Japanese journal of clinical hematology 1996;37(5):369-79.
1996: Anderlini P; Luna M; Kantarjian H M; O'Brien S; Pierce S; Keating M J; Estey E H
Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(4):600-8.
1996: Robertson L E; Plunkett W; McConnell K; Keating M J; McDonnell T J
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(3):456-9.
1996: Kantarjian H M; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang L Y; Rios M B; Keating M J; Meyer M
Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(3):396-401.
1996: Gandhi V; Estey E; Keating M J; Chucrallah A; Plunkett W
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Blood 1996;87(1):256-64.
1996: O'Brien S; Kantarjian H; Keating M J
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7 Suppl 6():S27-33.
1996: Robertson L E; Denny A W; Huh Y O; Plunkett W; Keating M J; Nelson J A
Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine.
Cancer chemotherapy and pharmacology 1996;37(5):445-50.
1995: Wright S J; Keating M J
Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role?
Leukemia & lymphoma 1995;20(1-2):131-6.
1995: Cortes J; O'Brien S M; Pierce S; Keating M J; Freireich E J; Kantarjian H M
The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia.
Blood 1995;86(6):2091-7.
1995: Robertson L E; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating M J
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(9):1444-9.
1995: Seymour J F; Robertson L E; O'Brien S; Lerner S; Keating M J
Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.
Leukemia & lymphoma 1995;18(5-6):493-6.
1995: O'Brien S; Kantarjian H; Beran M; Robertson L E; Koller C; Lerner S; Keating M J
Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
Blood 1995;86(4):1298-300.
1995: Haidar M A; Cao X B; Manshouri T; Chan L L; Glassman A; Kantarjian H M; Keating M J; Beran M S; Albitar M
p16INK4A and p15INK4B gene deletions in primary leukemias.
Blood 1995;86(1):311-5.
1995: Estey E; Keating M J; Pierce S; Stass S
Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):972-6.
1995: Robertson L E; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Keating M J
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(6):943-5.
1995: Yang L Y; Li L; Keating M J; Plunkett W
Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Molecular pharmacology 1995;47(5):1072-9.
1995: Bueso-Ramos C E; Manshouri T; Haidar M A; Huh Y O; Keating M J; Albitar M
Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis.
Leukemia & lymphoma 1995;17(1-2):13-8.
1995: Gandhi V; Estey E; Du M; Nowak B; Keating M J; Plunkett W
Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(2):169-78.
1994: Robertson L E; Estey E; Kantarjian H; Koller C; O'Brien S; Brown B; Keating M J
Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(12):2047-51.
1994: Wright S J; Robertson L E; O'Brien S; Plunkett W; Keating M J
The role of fludarabine in hematological malignancies.
Blood reviews 1994;8(3):125-34.
1994: Kantarjian H M; O'Brien S; Smith T; Estey E H; Beran M; Preti A; Pierce S; Keating M J
Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen.
British journal of haematology 1994;88(1):94-100.
1994: Ghaddar H M; Plunkett W; Kantarjian H M; Pierce S; Freireich E J; Keating M J; Estey E H
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(8):1269-74.
1994: Seymour J F; Khouri I F; Champlin R E; Keating M J
Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review.
American journal of clinical oncology 1994;17(4):360-8.
1994: O'Brien S; Kurzrock R; Duvic M; Kantarjian H; Stass S; Robertson L E; Estey E; Pierce S; Keating M J
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.
Blood 1994;84(3):733-8.
1994: Seymour J F; Pierce S A; Kantarjian H M; Keating M J; Estey E H
Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1994;8(5):823-6.
1994: Khouri I F; Keating M J; Vriesendorp H M; Reading C L; Przepiorka D; Huh Y O; Andersson B S; van Besien K W; Mehra R C; Giralt S A
Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):748-58.
1994: Mourad W A; Pugh W C; Huh Y O; Keating M J
Cell kinetic analysis of interleukin-2 receptor-tested chronic lymphocytic leukemia using the AgNOR silver stain.
American journal of clinical pathology 1994;101(3):300-4.
1994: Huh Y O; Pugh W C; Kantarjian H M; Stass S A; Cork A; Trujillo J M; Keating M J
Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody.
American journal of clinical pathology 1994;101(3):283-9.
1994: Keating M J; O'Brien S; Plunkett W; Robertson L E; Gandhi V; Estey E; Dimopoulos M; Cabanillas F; Kemena A; Kantarjian H
Fludarabine phosphate: a new active agent in hematologic malignancies.
Seminars in hematology 1994;31(1):28-39.
1994: Keating M J; McLaughlin P; Plunkett W; Robertson L E; O'Brien S; Gandhi V; Gregoire V; Yang L; Cabanillas F
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 2():79-83.
1994: Gandhi V; Robertson L E; Keating M J; Plunkett W
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology.
Cancer chemotherapy and pharmacology 1994;34(1):30-6.
1994: Keating M J; O'Brien S; Robertson L E; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Li Y Y; Gandhi V
The expanding role of fludarabine in hematologic malignancies.
Leukemia & lymphoma 1994;14 Suppl 2():11-6.
1994: Keating M J; Estey E; O'Brien S; Kantarjian H; Robertson L E; Plunkett W
Clinical experience with fludarabine in leukaemia.
Drugs 1994;47 Suppl 6():39-49.
1993: Kantarjian H M; Estey E; O'Brien S; Anaissie E; Beran M; Pierce S; Robertson L; Keating M J
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
Cancer 1993;72(10):2950-5.
1993: Robertson L E; Pugh W; O'Brien S; Kantarjian H; Hirsch-Ginsberg C; Cork A; McLaughlin P; Cabanillas F; Keating M J
Richter's syndrome: a report on 39 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(10):1985-9.
1993: Plunkett W; Gandhi V; Huang P; Robertson L E; Yang L Y; Gregoire V; Estey E; Keating M J
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Seminars in oncology 1993;20(5 Suppl 7):2-12.
1993: Keating M J; O'Brien S; Robertson L E; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang L Y; Gandhi V
New initiatives with fludarabine monophosphate in hematologic malignancies.
Seminars in oncology 1993;20(5 Suppl 7):13-20.
1993: Dimopoulos M A; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating M J
Fludarabine therapy in Waldenström's macroglobulinemia.
The American journal of medicine 1993;95(1):49-52.
1993: Keating M J; O'Brien S; Kantarjian H; Plunkett W; Estey E; Koller C; Beran M; Freireich E J
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.
Blood 1993;81(11):2878-84.
1993: Kemena A; O'Brien S; Kantarjian H; Robertson L; Koller C; Beran M; Estey E; Plunkett W; Lerner S; Keating M J
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Leukemia & lymphoma 1993;10(3):187-93.
1993: Gandhi V; Kemena A; Keating M J; Plunkett W
Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy.
Leukemia & lymphoma 1993;10(1-2):49-56.
1993: Robertson L E; Hall R; Keating M J; Estey E; Kantarjian H M; McLaughlin P; Hagemeister F B; Plunkett W
High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis.
Leukemia & lymphoma 1993;10(1-2):43-8.
1993: Escudier S M; Pereira-Leahy J M; Drach J W; Weier H U; Goodacre A M; Cork M A; Trujillo J M; Keating M J; Andreeff M
Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia.
Blood 1993;81(10):2702-7.
1993: Estey E; Plunkett W; Gandhi V; Rios M B; Kantarjian H; Keating M J
Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.
Leukemia & lymphoma 1993;9(4-5):343-50.
1993: Kantarjian H M; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios M B; Plunkett W; Keating M J
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Blood 1993;81(5):1146-51.
1993: Dimopoulos M A; Kantarjian H; Estey E; O'Brien S; Delasalle K; Keating M J; Freireich E J; Alexanian R
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine.
Annals of internal medicine 1993;118(3):195-8.
1993: Kantarjian H M; Estey E H; Keating M J
Treatment of therapy-related leukemia and myelodysplastic syndrome.
Hematology/oncology clinics of North America 1993;7(1):81-107.
1993: Gandhi V; Estey E; Keating M J; Plunkett W
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(1):116-24.
1993: Feldman E J; Keating M J
Fludarabine in the treatment of lymphoproliferative malignancies.
Cancer investigation 1993;11(3):314-8.
1993: Keating M J; Holmes R; Lerner S; Ho D H
L-asparaginase and PEG asparaginase--past, present, and future.
Leukemia & lymphoma 1993;10 Suppl():153-7.
1993: Estey E H; Plunkett W; Kantarjian H; Rios M B; Keating M J
Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.
Leukemia & lymphoma 1993;10 Suppl():115-21.
1993: Gandhi V; Estey E; Keating M J; Plunkett W
Biochemical modulation of arabinosylcytosine for therapy of leukemias.
Leukemia & lymphoma 1993;10 Suppl():109-14.
1993: Keating M J; O'Brien S; Robertson L; Huh Y; Kantarjian H; Plunkett W
Chronic lymphocytic leukemia--correlation of response and survival.
Leukemia & lymphoma 1993;11 Suppl 2():167-75.
1993: Keating M J; O'Brien S; Kantarjian H; Robertson L B; Koller C; Beran M; Estey E
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
Leukemia & lymphoma 1993;10 Suppl():139-45.
1993: Dimopoulos M A; O'Brien S; Kantarjian H; Estey E E; Keating M J; Alexanian R
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Leukemia & lymphoma 1993;11 Suppl 2():105-8.
1993: Robertson L E; Keating M J
Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.
Cancer treatment and research 1993;64():105-19.
1992: Robertson L E; Huh Y O; Butler J J; Pugh W C; Hirsch-Ginsberg C; Stass S; Kantarjian H; Keating M J
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.
Blood 1992;80(1):29-36.
1992: Freireich E J; Cork A; Stass S A; McCredie K B; Keating M J; Estey E H; Kantarjian H M; Trujillo J M
Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6(6):500-6.
1992: Kantarjian H M; Keating M J; Estey E H; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):772-8.
1992: Redman J R; Cabanillas F; Velasquez W S; McLaughlin P; Hagemeister F B; Swan F; Rodriguez M A; Plunkett W K; Keating M J
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):790-4.
1992: Kantarjian H M; Talpaz M; Kontoyiannis D; Gutterman J; Keating M J; Estey E H; O'Brien S; Rios M B; Beran M; Deisseroth A
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):398-405.
1992: Gandhi V; Kemena A; Keating M J; Plunkett W
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
Cancer research 1992;52(4):897-903.
1992: Kantarjian H M; Estey E H; O'Brien S; Anaissie E; Beran M; Rios M B; Keating M J; Gutterman J
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Blood 1992;79(4):876-81.
1992: Estey E H; Kurzrock R; Kantarjian H M; O'Brien S M; McCredie K B; Beran M; Koller C; Keating M J; Hirsch-Ginsberg C; Huh Y O
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
Blood 1992;79(4):882-7.
1992: Keating M J; Estey E; Kantarjian H; Plunkett W; O'Brien S; Koller C; Beran M; Freireich E J
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 2():78-80.
1991: Kantarjian H M; Talpaz M; Dhingra K; Estey E; Keating M J; Ku S; Trujillo J; Huh Y; Stass S; Kurzrock R
Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia.
Blood 1991;78(9):2411-8.
1991: Robertson L E; Keating M J
Therapeutic approaches to chronic lymphocytic leukemia.
Texas medicine 1991;87(11):68-74.
1991: Kantarjian H M; Talpaz M; Keating M J; Estey E H; O'Brien S; Beran M; McCredie K B; Gutterman J; Freireich E J
Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 1991;68(6):1201-7.
1991: Estey E H; Kurzrock R; Talpaz M; McCredie K B; O'Brien S; Kantarjian H M; Keating M J; Deisseroth A B; Gutterman J U
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
British journal of haematology 1991;77(3):291-5.
1991: Kantarjian H M; Schachner J; Keating M J
Fludarabine therapy in hairy cell leukemia.
Cancer 1991;67(5):1291-3.
1991: Kantarjian H M; Childs C; O'Brien S; Huh Y; Beran M; Schachner J; Koller C; Keating M J
Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia.
The American journal of medicine 1991;90(2):223-8.
1991: Keating M J; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs C C; Freireich E J; McCredie K B
Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):44-9.
1990: Walters R; Kantarjian H M; Keating M J; Estey E H; Trujillo J; Cork A; McCredie K B; Freireich E J
The importance of cytogenetic studies in adult acute lymphocytic leukemia.
The American journal of medicine 1990;89(5):579-87.
1990: Grunewald R; Kantarjian H; Keating M J; Abbruzzese J; Tarassoff P; Plunkett W
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Cancer research 1990;50(21):6823-6.
1990: Kantarjian H M; Redman J R; Keating M J
Fludarabine phosphate therapy in other lymphoid malignancies.
Seminars in oncology 1990;17(5 Suppl 8):66-70.
1990: Keating M J
Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.
Seminars in oncology 1990;17(5 Suppl 8):49-62.
1990: Kantarjian H M; Walters R S; Keating M J; Smith T L; O'Brien S; Estey E H; Huh Y O; Spinolo J; Dicke K; Barlogie B
Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):994-1004.
1990: Estey E H; Dixon D; Kantarjian H M; Keating M J; McCredie K; Bodey G P; Kurzrock R; Talpaz M; Freireich E J; Deisseroth A B
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor.
Blood 1990;75(9):1766-9.
1990: Kantarjian H M; Alexanian R; Koller C A; Kurzrock R; Keating M J
Fludarabine therapy in macroglobulinemic lymphoma.
Blood 1990;75(10):1928-31.
1990: Vadhan-Raj S; Velasquez W S; Butler J J; LeMaistre A; Lepe-Zuniga J; Keating M J; Koller C A; Gutterman J U
Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor.
American journal of hematology 1990;33(3):189-97.
1990: Andersson B S; Luna M A; Yee C; Hui K K; Keating M J; McCredie K B
Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia.
Cancer 1990;65(5):1079-84.
1990: Estey E H; Keating M J; McCredie K B; Freireich E J; Plunkett W
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1990;4(2):95-9.
1990: Kantarjian H M; Keating M J; Smith T L; Talpaz M; McCredie K B
Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia.
The American journal of medicine 1990;88(1):1-8.
1990: Kantarjian H M; Walters R L; Keating M J; Estey E H; O'Brien S; Schachner J; McCredie K B; Freireich E J
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia.
Cancer 1990;65(1):5-8.
1990: Estey E H; Kantarjian H M; Beran M; McCredie K B; Keating M J; Deisseroth A; Gutterman J U
Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF.
Haematology and blood transfusion 1990;33():732-6.
1990: Keating M J; Kantarjian H; Estey E; Plunkett W; Trujillo J; McCredie K B
Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia.
Haematology and blood transfusion 1990;33():593-603.
1989: Gandhi V; Nowak B; Keating M J; Plunkett W
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
Blood 1989;74(6):2070-5.
1989: Keating M J; Kantarjian H; Smith T L; Estey E; Walters R; Andersson B; Beran M; McCredie K B; Freireich E J
Response to salvage therapy and survival after relapse in acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(8):1071-80.
1989: Kantarjian H M; Walters R S; Keating M J; Barlogie B; McCredie K B; Freireich E J
Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia.
Cancer 1989;64(1):16-22.
1989: Keating M J; Kantarjian H; Talpaz M; Redman J; Koller C; Barlogie B; Velasquez W; Plunkett W; Freireich E J; McCredie K B
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.
Blood 1989;74(1):19-25.
1989: Heinemann V; Estey E; Keating M J; Plunkett W
Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(5):622-8.
1989: Estey E; Smith T L; Keating M J; McCredie K B; Gehan E A; Freireich E J
Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1989;3(4):257-63.
1989: Kantarjian H M; Keating M J; Walters R S; Koller C A; McCredie K B; Freireich E J
Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.
Cancer 1989;63(5):813-7.
1989: Horwitz L J; Kantarjian H M; Jagannath S; Keating M J; McCredie K B; Spitzer G; Vellekoop L; Zander A R; Dicke K A
Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia.
Bone marrow transplantation 1989;4(1):101-5.
1989: Ventura G J; Hester J P; Dixon D O; Khorana S; Keating M J
Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia.
Hematologic pathology 1989;3(1):23-8.
1988: Kantarjian H M; Walters R S; Smith T L; Keating M J; Barlogie B; McCredie K B; Freireich E J
Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia.
Blood 1988;72(5):1784-9.
1988: Keating M J; Smith T L; Kantarjian H; Cork A; Walters R; Trujillo J M; McCredie K B; Gehan E A; Freireich E J
Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1988;2(7):403-12.
1988: Kantarjian H M; Dixon D; Keating M J; Talpaz M; Walters R S; McCredie K B; Freireich E J
Characteristics of accelerated disease in chronic myelogenous leukemia.
Cancer 1988;61(7):1441-6.
1988: Kantarjian H M; Keating M J; Walters R S; McCredie K B; Freireich E J
The characteristics and outcome of patients with late relapse acute myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(2):232-8.
1988: Ventura G J; Hester J P; Smith T L; Keating M J
Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction.
American journal of hematology 1988;27(1):34-7.
1988: Keating M J; Kantarjian H; Talpaz M; Redman J; McCredie K B
Fludarabine therapy in chronic lymphocytic leukemia (CLL).
Nouvelle revue française d'hématologie 1988;30(5-6):461-6.
1987: Kantarjian H M; Keating M J
Therapy-related leukemia and myelodysplastic syndrome.
Seminars in oncology 1987;14(4):435-43.
1987: Estey E H; Keating M J; McCredie K B; Freireich E J
Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia.
Cancer treatment reports 1987;71(11):1113-4.
1987: Kantarjian H M; Keating M J; McCredie K B; Walters R; Talpaz M; Smith T L; Freireich E J
Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia.
Southern medical journal 1987;80(10):1228-32.
1987: Kantarjian H M; Keating M J; Talpaz M; Walters R S; Smith T L; Cork A; McCredie K B; Freireich E J
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.
The American journal of medicine 1987;83(3):445-54.
1987: Estey E H; Keating M J; Dixon D O; Trujillo J M; McCredie K B; Freireich E J
Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Hematologic pathology 1987;1(4):203-8.
1987: Ventura G J; Drewinko B; Keating M J
Correlative patterns of neutrophil and platelet counts during very early remission of acute myeloblastic leukemia.
Hematologic pathology 1987;1(2):113-6.
1987: Dalton W T; Ahearn M J; Cork A; Trujillo J M; Keating M J; McCredie K B; Freireich E J; Stass S A
Acute myelomonocytic leukemia associated with abnormalities of chromosome 16: a light and electron microscopic study.
Hematologic pathology 1987;1(2):105-12.
1987: Keating M J; Estey E; Kantarjian H M; Walters R; Smith T; McCredie K B; Freireich E J
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
Acta haematologica 1987;78 Suppl 1():120-6.
1987: Lee M S; Chang K S; Trujillo J M; McCredie K B; Keating M J; Freireich E J; Stass S A
T-cell receptor gamma chain gene rearrangement in acute myelogenous leukemia--evidence for lymphoid lineage prematurity.
Hematologic pathology 1987;1(2):93-8.
1986: Kantarjian H M; Keating M J; Walters R S; Estey E H; McCredie K B; Smith T L; Dalton W T; Cork A; Trujillo J M; Freireich E J
Acute promyelocytic leukemia. M.D. Anderson Hospital experience.
The American journal of medicine 1986;80(5):789-97.
1985: Holmes R; Keating M J; Cork A; Broach Y; Trujillo J; Dalton W T; McCredie K B; Freireich E J
A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22).
Blood 1985;65(5):1071-8.
1983: Maddox A M; Keating M J; Trujillo J; Cork A; Youness E; Ahearn M J; McCredie K B; Freireich E J
Philadelphia chromosome-positive adult acute leukemia with monosomy of chromosome number seven: a subgroup with poor response to therapy.
Leukemia research 1983;7(4):509-22.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Michael Keating

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Michael Keating (preview)

All Publications